58103-08-5

Basic information

• Product Name: ethyl [4-(diphenylmethyl)piperazin-1-yl]acetate
• Synonyms: 1-piperazineacetic acid, 4-(diphenylmethyl)-, ethyl ester
• CAS NO: 58103-08-5
• Molecular Formula: C₂₁H₂₆N₂O₂
• Molecular Weight: 338.4433
• Mol File: 58103-08-5.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 441.5°C at 760 mmHg
• Flash Point: 220.8°C
• Density: 1.11g/cm³
• Vapor Pressure: 5.42E-08mmHg at 25°C
• Refractive Index: 1.566
• CAS DataBase Reference: ethyl [4-(diphenylmethyl)piperazin-1-yl]acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl [4-(diphenylmethyl)piperazin-1-yl]acetate(58103-08-5)
• EPA Substance Registry System: ethyl [4-(diphenylmethyl)piperazin-1-yl]acetate(58103-08-5)

Safety Data

• Hazardous Substances Data: 58103-08-5(Hazardous Substances Data)

Upstream product

• 841-77-0 diphenylmethylpiperazine 
• 105-36-2 ethyl bromoacetate 
• 82-92-8 N-benzhydryl-N'-methylpiperazine 
• 102552-76-1 1-benzhydryl-4-(ethoxycarbonyl)piperazine 
• 105-39-5 chloroacetic acid ethyl ester 

Downstream Products

• 157665-24-2 2-[4-(diphenylmethyl)-1-piperazinyl]-acetic acid 
• 1345843-74-4 2-(4-benzhydrylpiperazin-1-yl)acetohydrazide 

Relevant articles and documents

Design, synthesis, in vitro, and in silico studies of 1,2,4-triazole-piperazine hybrid derivatives as potential MAO inhibitors

Monoamine oxidases (MAOs) have become promising drug targets for the development of central nervous system agents. In recent research, it was shown that numerous piperazine derivatives exhibit hMAO inhibitory activity. Therefore, in this study, a novel se

Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents

In this paper, a series of podophyllotoxin piperazine acetate ester derivatives were synthesized and investigated due to their antiproliferation activity on different human cancer cell lines. Among the congeners, C5 manifested prominent cytotoxicity towar

Parallel synthesis and biological evaluation of 837 analogues of procaspase-activating compound 1 (PAC-1)

Procaspase-Activating Compound 1 (PAC-1) is an ortho-hydroxy N-acyl hydrazone that enhances the enzymatic activity of procaspase-3 in vitro and induces apoptosis in cancer cells. An analogue of PAC-1, called S-PAC-1, was evaluated in a veterinary clinical trial in pet dogs with lymphoma and found to have considerable potential as an anticancer agent. With the goal of identifying more potent compounds in this promising class of experimental therapeutics, a combinatorial library based on PAC-1 was created, and the compounds were evaluated for their ability to induce death of cancer cells in culture. For library construction, 31 hydrazides were condensed in parallel with 27 aldehydes to create 837 PAC-1 analogues, with an average purity of 91%. The compounds were evaluated for their ability to induce apoptosis in cancer cells, and through this work, six compounds were discovered to be substantially more potent than PAC-1 and S-PAC-1. These six hits were further evaluated for their ability to relieve zinc-mediated inhibition of procaspase-3 in vitro. In general, the newly identified hit compounds are two- to four-fold more potent than PAC-1 and S-PAC-1 in cell culture, and thus have promise as experimental therapeutics for treatment of the many cancers that have elevated expression levels of procaspase-3.